- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02630563
Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids
April 19, 2016 updated by: Hoffmann-La Roche
A Study of the Safety, Tolerability and Pharmacokinetics of Oral CellCept® (Mycophenolate Mofetil, MMF) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids
The study is planned to be conducted in 2 parts.
The first part (open label, multi-center, non-controlled) of the study will estimate a dose that would provide a mycophenolic acid (MPA) exposure in pediatric participant that is comparable to that achieved in adult liver transplant participants receiving the approved dose of mycophenolate mofetil (MMF, CellCept).
The second part (open-label, multi-center, single-arm Phase IV study) of the study will provide the pharmacokinetics, efficacy and safety profile of the proposed dose in the immediate post-transplant period.
This study will be conducted at two centers based in the United States of America.
Twelve pediatric transplant participants receiving a first liver allograft from a cadaveric or living donor will be enrolled in this study.
Stable pediatric liver transplant participants who are at least 6 months post-transplant and who were already receiving stable dose of MMF in combination with cyclosporine will be enrolled into the study.
Participants should have received stable MMF dose according to center practice for at least seven days in order to get steady state pharmacokinetics (PK).
Participants also should have received stable concomitant doses of cyclosporine (for at least 2 days) and corticosteroids per center practice.
Participants will be aged between 9 months and 12 years, with at least 6 participants greater than or equal to (>/=) 9 months and less than (<) 36 months, of whom at least 2 will be <24 months.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143-0116
-
-
New York
-
New York, New York, United States, 10032-3784
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female participant must be between 3 months and 12 years of age
- Participant is a recipient of a first liver allograft from cadaveric or living donors
- Participant is a single-organ recipient (liver only)
- Female participants of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli International Units per milliliter (mIU/mL) within one week prior to PK sampling
- Female participants of childbearing potential must use two reliable forms of contraception simultaneously unless abstinence is the chosen method
- Effective contraception must be used before beginning of PK sampling
- Participants must be able to receive oral medication
- Participants must be at least 6 months post-transplant and had started on MMF in the early post-transplant period (within 2 weeks of transplant)
- Participants must be receiving stable doses of MMF per center practice for at least 7 days prior to PK sampling
- In addition, participants must be receiving stable doses of cyclosporine and corticosteroids, according to center practice
- Participants' parent/guardian are capable of understanding the purposes and risks of the study and must sign an informed consent for the study
Exclusion Criteria:
- Pregnant or nursing adolescents
- Participants who had undergone dialysis within two weeks before PK sampling
- Participants with active systemic infections
- Participants with absolute neutrophil counts (ANC) of less than 1300 per microliter (µL), or platelets counts less than 50 000/µL or hemoglobin at a concentration below a set lower limit (according to center practice, but not less than 8 grams per deciliter) at the time of study entry
- Participants with active peptic ulcer disease
- Participants with severe diarrhea (more than 5 watery stools per day) or other gastrointestinal disorders which might interfere with their ability to absorb oral medication
- History of positive human immunodeficiency virus (HIV) test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mycophenolate Mofetil+Corticosteroids+Cyclosporine
Part 1: Participants will receive mycophenolate mofetil.
Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
|
Corticosteroids will be administered as per center practice.
The choice of corticosteroid drug will also be based on center practice.
Cyclosporine will be administered as per center practice.
Part 1: Mycophenolate mofetil will be administered as per center practice.
Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours of Mycophenolic Acid Normalized for Dose And for Body Surface Area
Time Frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
The area under the plasma concentration-time curve from time zero to twelve hours (AUC [0-12h]) is area under the plasma concentration-time curve from time zero through 12 hours.
AUC (0-12) hours was computed using the linear trapezoidal rule.
For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile.
When such values appeared at the end of a profile they were assigned as missing data.
AUC0-12h was normalized to 600 milligram per square meter (mg/m^2) and 1.5 gram.
AUC was reported in microgram hour per milliliter (mcg*h/mL).
|
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration Time Curve From 0-12 Hours for Mycophenolic Acid and Mycophenolic Acid Glucuronide Phenolic Glucuronide of Mycophenolic Acid
Time Frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
The area under the plasma concentration-time curve from time zero to twelve hours (AUC [0-12h]) is area under the plasma concentration-time curve from time zero through 12 hours.
AUC (0-12) hours was computed using the linear trapezoidal rule.
For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile.
When such values appeared at the end of a profile they were assigned as missing data.
AUC was reported in microgram hour per milliliter (mcg*h/mL).
|
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide
Time Frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
|
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
Cmax was obtained directly from the measured plasma concentration-time curves.
|
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
|
Time to Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide
Time Frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
|
Tmax is the amount of time after dosing to when the maximum concentration of MPA and MPAG was achieved.
|
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
|
Number of Participants With Adverse Events and Serious Adverse Events
Time Frame: Up to Day 32
|
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.
|
Up to Day 32
|
Plasma Concentration of Mycophenolic Acid and Its Metabolite Mycophenolic Acid Glucuronide at Each Time Point
Time Frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
Mycophenolic Acid Glucuronide (MPAG) is an active metabolite of Mycophenolic Acid (MPA).
|
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2003
Primary Completion (Actual)
January 1, 2005
Study Completion (Actual)
January 1, 2005
Study Registration Dates
First Submitted
December 11, 2015
First Submitted That Met QC Criteria
December 14, 2015
First Posted (Estimate)
December 15, 2015
Study Record Updates
Last Update Posted (Estimate)
May 19, 2016
Last Update Submitted That Met QC Criteria
April 19, 2016
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Mycophenolic Acid
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- PA16497
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Liver Transplantation
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingPediatric Liver TransplantationIndia
-
Assiut UniversityUnknownPediatric Liver TransplantationEgypt
-
University Hospital TuebingenUnknownPediatric Liver TransplantationGermany
-
Cliniques universitaires Saint-Luc- Université...UnknownPediatric Liver TransplantationBelgium
-
RenJi HospitalRecruitingPediatric Patients Who Need Liver TransplantationChina
-
Bambino Gesù Hospital and Research InstituteCatholic University of the Sacred HeartUnknownWeaning From Mechanical Ventilation | Pediatric Liver TransplantationItaly
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
RenJi HospitalRecruitingPostoperative Complications | Developmental Delay | Pediatric Liver Transplantation | Socioemotional DelayChina
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
Clinical Trials on Corticosteroids
-
Peking Union Medical College HospitalRecruitingSevere Checkpoint Inhibitor PneumonitisChina
-
Sohag UniversityRecruitingBronchial AsthmaEgypt
-
Wayne State UniversityChildren's Hospital of Fudan UniversityTerminatedNephrotic Syndrome in ChildrenChina, United States
-
Bispebjerg HospitalUnknown
-
St. Louis UniversityCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma
-
Central Hospital, Nancy, FranceUnknownAcute Respiratory Distress Syndrome Secondary to Covid-19France
-
Soroka University Medical CenterUnknownAsthma ExacerbationIsrael
-
Sun Yat-sen UniversityNot yet recruitingArtificial Intelligence | Eye Involvement of Systemic Diseaes | Adverse Drug Effect on Eye
-
Assiut UniversityAssociation for Training, Education, and Research in Hematology, Immunology...Not yet recruitingITP - Immune Thrombocytopenia